• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
February 5th - Shanghai Henlius Biotech (02696.HK) announced that it has entered into a licensing agreement with Japanese pharmaceutical company Eisai Co., Ltd., under which the company will grant Eisai an exclusive license to commercialize its licensed product Hanszal® (Slulimab injection) in the region and field. Eisai will pay the company an upfront payment of US$75 million, regulatory milestone payments totaling up to US$80.01 million based on the achievement of various regulatory milestones for the licensed product in the region, and commercial sales milestone payments totaling up to US$233.33 million based on the achievement of annual net sales of the licensed product in the region, plus royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region.Volkswagen shares fell 3.2%, poised for their biggest one-day drop since September 2025.February 5th - Hengrui Medicine announced that it recently received an Acceptance Notice from the National Medical Products Administration (NMPA) for its marketing authorization application for HR091506 tablets. HR091506 tablets are febuxostat oral sustained-release tablets with pulsatile release characteristics, independently developed by the company using gastric retention formulation technology. The product consists of an immediate-release portion and a delayed-release portion. After oral administration, the immediate-release portion is rapidly released in the stomach to achieve an effective blood drug concentration; the delayed-release portion remains in the stomach for sustained release, aiming to prolong the duration of effective blood drug concentration and improve the rate of uric acid reduction.February 5th – A meeting on financial support for the construction of the Western Land-Sea New Corridor was held in Chongqing on the morning of February 5th. Pan Gongsheng, Secretary of the Party Committee and Governor of the Peoples Bank of China (PBOC), stated that providing financial support for the construction of the Western Land-Sea New Corridor is a crucial responsibility of the PBOC and the financial system. The PBOC will continue to support the accelerated construction of the Western Land-Sea New Corridor, strengthen coordination with provinces (autonomous regions and municipalities) along the corridor, support the continuous construction and development of the financial services and infrastructure system of the Western Land-Sea New Corridor with Chongqing as a hub, promote the interconnection and optimization of financial elements, enrich and develop the financial services and product system, enhance the precision and effectiveness of financial support, coordinate high-level financial opening-up and security, improve the facilitation of cross-border trade settlement and investment and financing along the corridor, optimize cross-border financial services, and better serve the construction of the Western Land-Sea New Corridor and the high-quality development of the western region.Statoil: Starting February 1 this year, it will supply gas to the Dutch gas pipeline network, with an annual supply of up to 500 million cubic meters.

S&P 500 Rallies 0.5%, Netflix Gains Nearly 7% on Upbeat Subscriber Outlook

Cory Russell

Jul 21, 2022 15:17

微信截图_20220721151043.png

All Major US Indices Remain Above 50DMA as S&P 500 and Nasdaq 100 Rally

The major US market indices were mixed on Wednesday, with the S&P 500 and Nasdaq 100 indexes doing better than the Dow Jones Industrial Average despite being more heavily weighted toward large technology and growth stocks. The first two were both successful in reaching their highest points in almost a month.


The fact that all three of the main indexes were able to retake their 50-Day Moving Averages for the first time since April is one important finding from the US equities markets on Wednesday, suggesting that the current bullish change in momentum may have more legs.


According to analysts, the main indexes are benefiting from the US earnings season's better-than-expected start. After the closing, the electric vehicle manufacturer Tesla is scheduled to release its profits.


Data suggesting that existing house sales fell to a two-year low in June after surging to record highs during the epidemic last summer were ignored by US equities markets. The US home market has recently suffered from a sluggish economy, a deteriorating cost-of-living issue, and a dramatic increase in interest rates.


Despite the grim forecast, most existing houses sold in June were listed for less than a month, according to LPL Financial's chief economist Jeffrey Roach, who was reported by Reuters. This suggests that despite a weakening economy, there is still a fundamental need for house ownership.

Large-Cap Growth Stocks Are the Front-Runners

Stronger than anticipated Netflix results sent the company's share price higher, driving the rise in the US equities markets on Wednesday. These huge tech/growth stock dominated information technology and consumer discretionary GICS S&P 500 sectors. The streaming service said that it lost roughly 1 million customers in the second quarter but anticipated that its subscriber count will begin to increase once again in the third quarter.


Other members of the once-dominant FAANG group of companies rallied in response to Netflix's positive Q3 projection. FAANG stands for Google, Apple, Amazon, Netflix, and Facebook (now known as Meta Platforms) (whose parent company is called Alphabet). By the end of the next week, Alphabet, Meta, and Amazon will all have released their results.


Semiconductor manufacturers were another significant outperforming segment of the US equities market. Analysts pointed to the fact that the US Senate approved measures aimed at bolstering the US semiconductor sector on Tuesday as the reason for the Philadelphia Semiconductor index's increase of more than 2% on Wednesday.


The share price of Merck & Co. decreased after the cancer treatment medicine Keytruda failed to reach end-point goals in a late-stage neck and head cancer study, one of the significant individual movers.